P555: OLUTASIDENIB IN POST-VENETOCLAX PATIENTS WITH MUTANT IDH1 AML

• Jorge Cortes,
• Justin M. Watts,
• Gary Schiller,
• Leslie Todd,
• Aaron Sheppard,
• Brian A. Jonas

Affiliations

Jorge Cortes

1 Augusta University, Georgia Cancer Center, Augusta, United States

Justin M. Watts

2 University of Miami Sylvester Comprehensive Cancer Center, Miami, United States

Gary Schiller

3 David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, United States

Leslie Todd

4 Rigel Pharmaceuticals, Inc., South San Francisco, United States

Aaron Sheppard

4 Rigel Pharmaceuticals, Inc., South San Francisco, United States

Brian A. Jonas

5 UC Davis Comprehensive Cancer Center, Sacramento, United States